Royalty Pharma (RPRX) Short-term Investments (2019 - 2026)
Royalty Pharma (RPRX) posted Short-term Investments of $21.9 million for Q1 2026, up 16.49% sequentially from $18.8 million in Q4 2025, and up 80.99% YoY from $12.1 million in Q1 2025.
Royalty Pharma (RPRX) Short-term Investments (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Short-term Investments for 8 years, with the latest figure at $21.9 million in Q1 2026.
- Quarterly Short-term Investments rose 80.99% year-over-year to $21.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.9 million (up 80.99% YoY) and the FY2025 annual result came in at $18.8 million, down 67.7% from the prior year.
- Short-term Investments improved to $21.9 million in Q1 2026 per RPRX's latest filing, from $18.8 million in the prior quarter.
- Over five years, Short-term Investments peaked at $409.3 million in Q3 2022 and troughed at $5.3 million in Q3 2023.
- A 5-year average of $76.1 million and a median of $24.4 million in 2022 frame the typical range for Short-term Investments.
- The sharpest annual moves came in 2023 and 2024: Short-term Investments plunged 98.71% in 2023, then surged 815.09% in 2024.
- Over 5 years, Short-term Investments stood at $24.4 million in 2022, then slipped by 25.06% to $18.3 million in 2023, then surged by 218.03% to $58.2 million in 2024, then tumbled by 67.7% to $18.8 million in 2025, then advanced by 16.49% to $21.9 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered $21.9 million, $18.8 million, and $16.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.00 Mn |
| Mar 31, 2026 | 21.90 Mn |
| Dec 31, 2025 | 18.80 Mn |
| Sep 30, 2025 | 16.10 Mn |
| Jun 30, 2025 | 13.20 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Dec 31, 2024 | 58.20 Mn |
| Sep 30, 2024 | 48.50 Mn |
| Jun 30, 2024 | 38.50 Mn |
| Mar 31, 2024 | 29.00 Mn |
| Dec 31, 2023 | 18.30 Mn |
| Sep 30, 2023 | 5.30 Mn |
| Dec 31, 2022 | 24.42 Mn |
| Sep 30, 2022 | 409.35 Mn |
| Jun 30, 2022 | 363.70 Mn |
| Mar 31, 2022 | 64.80 Mn |
| Dec 31, 2021 | 66.00 Mn |
| Sep 30, 2021 | 245.75 Mn |
| Jun 30, 2021 | 68.70 Mn |
| Mar 31, 2021 | 1.07 Bn |